COMBINED FINANCIAL STATEMENTS AND REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS

SEPTEMBER 30, 2023

TABLE OF CONTENTS

	<u>Page</u>
INDEPENDENT AUDITOR'S REPORT	1 - 2
FINANCIAL STATEMENTS	
Combined Statements of Financial Position, September 30, 2023 And 2022	3
Combined Statement of Activities And Change In Net Assets, Year Ended September 30, 2023 (With Summarized Financial Information From 2022)	4
<i>Combined Statement of Functional Expenses,</i> Year Ended September 30, 2023 (With Summarized Financial Information From 2022)	5
Combined Statements of Cash Flows, Years Ended September 30, 2023 And 2022	6
Notes To Financial Statements	7 - 20
SUPPLEMENTAL INFORMATION	
REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS ON SUPPLEMENTAL INFORMATION	21
Combining Statement of Financial Position, September 30, 2023	22
Combining Statement of Activities And Changes In Net Assets, Year Ended September 30, 2023	23



INDEPENDENT AUDITORS' REPORT

Board of Directors Planned Parenthood of Metropolitan Washington, D.C., Inc. and Affiliate Washington, D.C.

Opinion

We have audited the accompanying combined financial statements of Planned Parenthood of Metropolitan Washington, D.C., Inc. and affiliate ("PPMW") (a nonprofit organization) which comprise the combined statement of financial position as of September 30, 2023, and the related combined statements of activities and change in net assets, functional expenses and cash flows for the year then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the combined financial position of PPMW as of September 30, 2023, and the combined change in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of PPMW and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the combined financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about PPMW's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the combined financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements. In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of PPMW's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about PPMW 's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Report on Summarized Comparative Information

We have previously audited PPMW's 2022 combined financial statements, and we expressed an unmodified audit opinion on those audited financial statements in our report dated March 29, 2023. In our opinion, the summarized comparative information presented herein as of and for the year ended September 30, 2022, is consistent, in all material respects, with the audited combined financial statements from which it has been derived.

Tait, Weller & Baher CCP

Philadelphia, Pennsylvania May 31, 2024

COMBINED STATEMENTS OF FINANCIAL POSITION

September 30, 2023 and 2022

ASSETS	2023	2022
Cash and cash equivalents	\$ 1,142,431	\$ 2,797,798
Contributions receivable, net	2,185,353	935,542
Grants receivable	334,623	221,251
Patient receivables, net	234,072	308,542
Other receivables	74,603	130,428
Prepaid expenses and other current assets	568,797	248,754
Investments	10,072,373	13,144,257
Inventory	289,957	283,140
Operating right-of-use assets	322,703	-
Property and equipment, net of accumulated depreciation	22,102,083	20,077,751
Total assets	\$ 37,326,995	\$ 38,147,463
LIABILITIES AND NET ASSETS		
LIABILITIES		
Lines of credit	\$ 49,649	\$ 50,000
Accounts payable and accruals	1,986,958	1,848,008
Deferred revenue	34,613	-
Lease Liabilities	319,637	
Total liabilities	2,390,857	1,898,008
COMMITMENTS	-	-
NET ASSETS		
Without donor restrictions	32,068,738	34,441,873
With donor restrictions	2,867,400	1,807,582
Total net assets	34,936,138	36,249,455
Total liabilities and net assets	\$ 37,326,995	\$ 38,147,463

COMBINED STATEMENT OF ACTIVITIES AND CHANGES IN NET ASSETS

Year Ended September 30, 2023 With Summarized Financial Information for 2022

	Without Donor Restrictions	With Donor Restrictions	2023 Total	2022
REVENUES, GAINS AND OTHER SUPPORT				
Contributions	\$ 8,140,214	\$ 2,420,610	\$ 10,560,824	\$ 17,793,339
Grants and contracts revenue	1,136,608	1,231,338	2,367,946	1,594,822
Government assistance	-	-	-	1,308,335
Interest and dividend income	106,493	24,634	131,127	154,502
Contributed services	179,332	-	179,332	55,500
Patient service fees, net of charge adjustments	6,634,630	-	6,634,630	6,862,845
Other revenue	97,520	-	97,520	97,950
	16,294,797	3,676,582	19,971,379	27,867,293
Net assets released from restrictions	2,698,517	(2,698,517)		
TOTAL REVENUES, GAINS AND OTHER SUPPORT	18,993,314	978,065	19,971,379	27,867,293
EXPENSES				
Program Services				
Patient Services	14,289,453	-	14,289,453	12,204,660
External Affairs	1,048,379	-	1,048,379	752,503
Community Education	1,198,754	-	1,198,754	881,285
PPADMV	493,555		493,555	321,337
Total Program Services	17,030,141		17,030,141	14,159,785
Supporting Services				
Management and General	2,088,345	-	2,088,345	1,795,852
Fundraising	2,853,523	-	2,853,523	2,412,696
Total Supporting Services	4,941,868	-	4,941,868	4,208,548
TOTAL EXPENSES	21,972,009		21,972,009	18,368,333
CHANGE IN NET ASSETS FROM OPERATIONS	(2,978,695)	978,065	(2,000,630)	9,498,960
OTHER CHANGES				
Net appreciation (depreciation) on investments	605,560	81,753	687,313	(788,873)
Loss on contributions receivable				(7,000)
CHANGE IN NET ASSETS	(2,373,135)	1,059,818	(1,313,317)	8,703,087
NET ASSETS AT BEGINNING OF YEAR	34,441,873	1,807,582	36,249,455	27,546,368
NET ASSETS AT END OF YEAR	\$ 32,068,738	\$ 2,867,400	\$ 34,936,138	\$ 36,249,455

COMBINED STATEMENT OF FUNCTIONAL EXPENSES

Year Ended September 30, 2023 With Summarized Financial Information for 2022

		Program	Program Services Supporting Services			g Services		
	Patient Services	External Affairs	Community Education	PPADMV	Management General	Fundraising	2023 Total	2022
Salaries & Fringe Benefits	\$ 6,992,539	\$ 532,757	\$ 614,824	\$ 275,460	\$ 3,685,325	\$ 1,291,434	\$ 13,392,339	\$ 11,248,840
Medical and Direct Program Supplies	1,597,816	4,598	42,066	120	830	296	1,645,726	1,353,181
Contract Physicians	338,158	-	-	-	-	-	338,158	348,235
Professional Fees	1,107,354	121,211	42,286	91,698	923,363	723,854	3,009,766	2,221,734
Occupancy	301,550	9,688	20,520	2,090	59,429	14,088	407,365	427,331
Interest Expense	-	-	-	-	1,781	-	1,781	1,873
Supplies	99,587	12,565	46,603	-	49,301	5,364	213,420	166,234
Telephone	198,160	12,235	19,200	-	74,955	22,666	327,216	333,248
Postage & Shipping	8,682	693	9,859	35	3,622	763	23,654	18,868
Maintenance & Repairs	142,909	6,559	15,140	-	47,837	9,994	222,439	178,948
Equipment Rental	24,144	2,275	5,060	-	12,744	3,413	47,636	64,451
Conferences, Conventions & Meetings	63,379	22,621	22,914	36,799	111,558	361,226	618,497	352,135
Advertising and Publications	198,170	73,200	20,523	87,353	-	33,874	413,120	440,987
Insurance & Dues	277,524	57,068	28,450	-	176,865	44,289	584,196	479,676
Depreciation	464,200	19,083	51,767	-	157,887	33,703	726,640	732,592
Miscellaneous	33				23		56	
Total expenses before allocations	11,814,205	874,553	939,212	493,555	5,305,520	2,544,964	21,972,009	18,368,333
Allocation of management and general	2,475,248	173,826	259,542		(3,217,175)	308,559		
Total expenses	\$ 14,289,453	\$ 1,048,379	\$ 1,198,754	\$ 493,555	\$ 2,088,345	\$ 2,853,523	\$ 21,972,009	\$ 18,368,333

COMBINED STATEMENTS OF CASH FLOWS

Years Ended September 30, 2023 and 2022

Cash flows from operating activities \$ (1,313,317) \$ 8 22,471 Adjustments to reconcile change in net assets to net cash provided by operating activities 726,640 757,104 Depreciation 726,640 757,104 Amotization of fight-of-use assets 101,203 - Operating lease liability payments (1042,69) - Loss on disposal of property and equipment - 6,603 Na (appreciation) directication on investments (687,313) (703,284) Change in reserve in contributions (71,324) 249,256 Contributions receivable (113,727) 136,883 Pattern Receivables (167,086 (76,221) Other receivable (1249,811) 249,256 Grants receivable (1249,811) 249,256 Grants receivable (113,727) 136,885 Patterin Receivables (138,927) 15,706 Increase (decrease) in: - (20,645) - Accounts payable and accruals 34,613 - (20,657) Deferred revenue 34,613 - (20,657)		 2023	 2022
Change in net assets \$ (1,31,317) \$ 822,471 Adjustments to reconcile change in net assets to net cash provided by operating activities 726,640 757,104 Depreciation 726,640 757,104 Amorization of right-of-use assets 101,203 - Operating lease liability payments (104,269) - Loss on disposal of property and equipment - 6,605 Net (appreciation) enpreciation on investments (887,313) (703,284) Change in reserve in nation receivables (92,616) 13,074 (Increase) decrease in: (113,772) 136,883 Contributions receivables (113,772) 136,883 Draint receivables (13,723) 136,883 Draint Receivables (13,723) 136,883 Draint Receivables (13,723) 138,950 Journet Receivables (13,73) (6,817) Inveratory (6,817) 15,706 Increase (decrease) in: (23,043) 18,022 Defered revenue 34,613 - Refundable advance	Cash flows from operating activities		
provided by operating activities 726,640 757,104 Depreciation of right-of-use assets 101,203 - Class on disposal of property and equipment - 6605 Net (appreciation) depreciation on investments (104,269) - Change in reserve in patient receivables (20,2616) 13.074 Change in reserve in patient receivables (22,616) 13.074 (Increase) decrease in: - (23,023) Contributions receivable (1,249,811) 249.256 Grants receivable (13,372) 136.883 Patient Receivables 167,086 (76,517) Other receivables 55.825 2,106,150 Prepatie expenses and other current assets 138,950 309,562 Defered revenue - (20,445) - Increase (decrease) in: - - (20,451) - Accounts payable and accruals 138,950 309,562 - - (20,455) Net cash provided by operating activities (2,653,241) 3,611,840 - - (20,457)		\$ (1,313,317)	\$ 822,471
provided by operating activities 726,640 757,104 Depreciation of right-of-use assets 101,203 - Class on disposal of property and equipment - 6605 Net (appreciation) depreciation on investments (104,269) - Change in reserve in patient receivables (20,2616) 13.074 Change in reserve in patient receivables (22,616) 13.074 (Increase) decrease in: - (23,023) Contributions receivable (1,249,811) 249.256 Grants receivable (13,372) 136.883 Patient Receivables 167,086 (76,517) Other receivables 55.825 2,106,150 Prepatie expenses and other current assets 138,950 309,562 Defered revenue - (20,445) - Increase (decrease) in: - - (20,451) - Accounts payable and accruals 138,950 309,562 - - (20,455) Net cash provided by operating activities (2,653,241) 3,611,840 - - (20,457)			
Depreciation 726,640 757,104 Amortization of right-of-use assets 101,203 - Operating lease liability payments (104,269) - Loss on disposal of property and equipment - 6,605 Net (appreciation of prixetmats (87,313) (703,284) Change in reserve in contributions (23,023) - Change in reserve in patient receivables (113,372) 136,883 Patient Receivable (11,249,811) 249,256 Grants receivable (113,372) 136,883 Patient Receivables 167,086 (76,221) Other receivables 58,825 2,106,150 Prepaid expenses and other current assets (320,043) 18,022 Inventory (6,817) 15,706 Increase (decrease) in: - - (20,465) Accounts payable and accruals 138,950 309,562 - Accounts payable and accruals 138,950 309,562 - (20,465) Net cash provided by operating activities - - (20,465) -			
Amorization of right-of-use assets101.203.Operating lease liability payments(104,269).Loss on disposal of property and equipmentKet (appreciation) depreciation on investments(687,313)(703,284)Change in reserve in contributions(23,023)Change in reserve in patient receivables(92,616)13,074(Increase) decrease in:(23,023)Contributions receivable(11,249,811)249,256Contributions receivablesContributions receivablesOther receivablesOther receivablesOther receivablesOther receivables <td< td=""><td></td><td>726.640</td><td>757.104</td></td<>		726.640	757.104
Operating lesse liability payments (104,269) - 6,605 Loss on disposal of property and equipment - - 6,605 Net (appreciation of investments (687,313) (703,284) Change in reserve in contributions - (23,023) Change in reserve in patient receivables (113,372) 136,883 Contributions receivable (113,372) 136,883 Patient Receivables 155,825 2,106,150 Other receivables 155,825 2,106,150 Prepaid expenses and other current assets (320,043) 18,022 Inventory (6,817) 15,706 Increase (decrease) in: - (20,465) Accounts payable and accruals 138,950 309,562 Deferred revenue 34,613 - Accounts payable and accruals 138,950 309,562 Deferred revenue 34,613 - Accounts payable and accruals 138,950 309,562 Deferred revenue - (20,465) Purchases of propery and equipiment (2,750,972) <td< td=""><td>-</td><td></td><td>-</td></td<>	-		-
Loss on disposal of property and equipment6,605Net (appreciation) depreciation on investments(687,313)Change in reserve in contributions-(Increase) decrease in:(1,249,811)Contributions receivable(11,372)Change in reserve in patient receivables(11,372)(Increase) decrease in:(11,372)Contributions receivable(11,372)Intersective in patient receivables(11,372)Patient Receivables167,086(76,221)Other receivablesPrepaid expenses and other current assets(32,0043)Increase (decrease) in:188,950Accounts puyable and accruals138,950Joeferred revenue34,613Refundable advance-(20,465)(2,750,972)Purchase of property and equipment(2,750,972)Net cash provided by operating activities1,008,225Question financing activities(351)Net cash novided by (used in) investing activities1,008,225Net cash novided by (used in) investing activities(351)Net cash novided by (used in) investing activities(351)Net cash activities(351)Net cash used in financing activities(351)		<i>,</i>	-
Change in reserve in contributions(23,023)Change in reserve in patient receivables(92,616)(Increase) decrease in:(1249,811)Contributions receivable(113,372)Dittor receivables(113,372)Patient Receivables(113,372)Other receivables(13,372)Other receivables(13,372)Other receivables(13,372)Inventory(6,817)Increase (decrease) in:(23,043)Accounts payable and accruals(138,950)Accounts payable and accruals(24,645)Cash flows from investing activities(2,663,241)Othercase (decrease) of investing activities(2,663,241)Cash flows from investing activities(2,750,972)(Refrancese) decrease in money market funds(950,956)Purchase of property and equipment(2,750,972)Net cash provided by (used in) investing activities(351)Net cash provided by (used in) investing activities(351)Net cash flows from financing activities(351)Net cash used in financing acti	Loss on disposal of property and equipment	-	6,605
Change in reserve in patient receivables (92,616) 13,074 (Increase) decrease in: (1,249,811) 249,256 Contributions receivable (113,372) 136,883 Patient Receivables 167,086 (76,221) Other receivables 167,086 (76,221) Other receivables 55,825 2,106,150 Prepaid expenses and other current assets (320,043) 18,022 Inventory (6,817) 15,706 Increase (decrease) in: - - Accounts payable and accruals 138,950 309,562 Deferred revenue - - (20,465) Net cash provided by operating activities - - (20,465) Net cash provided by operating activities (2,750,972) (82,497) Net proceeds (purchases) of investiments 4,710,153 (897,078) Net cash provided by (used in) investing activities 1,008,225 (98,670) Cash flows from financing activities 1,008,225 (98,670) Net cash provided by (used in) investing activities (351) (1,811,771) Repayment of loan payable - (351) (1,	Net (appreciation) depreciation on investments	(687,313)	(703,284)
(Increase) decrease in: (1,249,811) 249,256 Grants receivable (113,372) 136,883 Patient Receivables 167,086 (76,221) Other receivables 55,825 2,106,150 Prepaid expenses and other current assets (320,043) 18,022 Inventory (6,817) 15,706 Increase (decrease) in: (6,817) 15,706 Accounts payable and accruals 138,950 309,562 Deferred revenue 34,613 - Refundable advance - (20,465) Net cash provided by operating activities (2,663,241) 3,611,840 Cash flows from investing activities (2,670,972) (82,497) Net proceeds (purchases) of investments (4,710,153) (897,078) Net cash provided by (used in) investing activities 1,008,225 (98,670) Cash flows from financing activities (351) (1,811,771) Repayment of loan payable - (885,477) Net cash used in financing activities (351) (1,625,367) 1,612,852 Cash and cash equivalents, beginning of the year 2,797,798 1,852,315 <tr< td=""><td>Change in reserve in contributions</td><td>-</td><td>(23,023)</td></tr<>	Change in reserve in contributions	-	(23,023)
Contributions receivable $(1,249,811)$ $249,256$ Grants receivable $(113,372)$ $136,883$ Patient Receivables $167,086$ $(76,221)$ Other receivables $55,825$ $2,106,150$ Prepaid expenses and other current assets $(320,043)$ $18,022$ Inventory $(6,817)$ $15,706$ Increase (decrease) in: $(22,663,241)$ $309,562$ Accounts payable and accuuals $138,950$ $309,562$ Deferred revenue $34,613$ -Refundable advance- $(20,465)$ Net cash provided by operating activities $(2,663,241)$ $3,611,840$ Cash flows from investing activities $(950,956)$ $880,905$ Purchase of property and equipment $(2,750,972)$ $(82,497)$ Net cash provided by (used in) investing activities $1,008,225$ $(98,670)$ Cash flows from financing activities $1,008,225$ $(98,670)$ Net cash provided by (used in) investing activities $1,008,225$ $(98,670)$ Net cash used in financing activities (351) $(1,811,771)$ Repayment of loan payable $ (88,547)$ Net (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS $(1,655,367)$ $1,612,852$ Cash and cash equivalents, end of the year $2,797,798$ $1,852,315$ Cash and cash equivalents, end of the year $5,1,781$ $5,3,465,167$ SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Interest paid during the year $5,1,781$ $5,1,873$	Change in reserve in patient receivables	(92,616)	13,074
Grants receivable (113,372) 136,883 Patient Receivables 167,086 (76,221) Other receivables 55,825 2,106,150 Prepaid expenses and other current assets (320,043) 18,022 Inventory (6,817) 15,706 Increase (decrease) in: (6,817) 15,706 Accounts payable and accruals 138,950 309,562 Deferred revenue 34,613 - Refundable advance - (20,465) Net cash provided by operating activities (2,663,241) 3,611,840 Cash flows from investing activities (2,750,972) (82,497) Net cash provided by (used in) investing activities 1,008,225 (98,670) Purchase of property and equipment (2,750,972) (82,497) Net cash provided by (used in) investing activities 1,008,225 (98,670) Cash flows from financing activities (351) (1,811,771) Repayment of loan payable - (85,547) (85,547) Net cash used in financing activities (351) (1,655,367) 1,612,852 Cash and cash equivalents, end of the year 2,797,798	(Increase) decrease in:		
Patient Receivables 167,086 (76,221) Other receivables 55,825 2,106,150 Prepaid expenses and other current assets (320,043) 18,022 Inventory (6,817) 15,706 Increase (decrease) in: - (20,463) Accounts payable and accruals 138,950 309,562 Deferred revenue 34,613 - Refundable advance - (20,465) Net cash provided by operating activities (2,663,241) 3,611,840 Cash flows from investing activities (2,750,972) (82,497) Net cash provided by operating activities (2,750,972) (82,497) Net proceeds (purchases) of investments 1,008,225 (98,670) Cash flows from financing activities 1,008,225 (98,670) Cash flows from financing activities (351) (1,811,771) Repayment of loan payable - (88,547) Net cash used in financing activities (351) (1,612,852 Cash and cash equivalents, beginning of the year 2,797,798 1,852,315 Cash and cash equivalents, end of the year \$ 1,142,431 \$ 3,465,167 <t< td=""><td></td><td></td><td></td></t<>			
Other receivables $55,825$ $2,106,150$ Prepaid expenses and other current assets $(320,043)$ $18,022$ Inventory $(6,817)$ $15,706$ Increase (decrease) in: Accounts payable and accruals $138,950$ $309,562$ Deferred revenue $34,613$ $-$ Refundable advance $ (20,465)$ Net cash provided by operating activities $(2,663,241)$ $3,611,840$ Cash flows from investing activities $(2,750,972)$ $(82,497)$ Net proceeds (purchases) of investments $4,710,153$ $(897,078)$ Net cash provided by (used in) investing activities $1,008,225$ $(98,670)$ Cash flows from financing activities (351) $(1,811,771)$ Repayment of loan payable $ (88,547)$ Net cash used in financing activities (351) $(1,690,318)$ NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS $(1,655,367)$ $1.612,852$ Cash and cash equivalents, beginning of the year $2,797,798$ $1.852,315$ Cash and cash equivalents, end of the year \underline{S} $1,781$ \underline{S} SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Interest paid during the year \underline{S} $1,781$ \underline{S} $1,873$			
Prepaid expenses and other current assets $(320,043)$ $18,022$ $(6,817)$ Inventory $(6,817)$ $15,706$ Increase (decrease) in: Accounts payable and accruals $138,950$ $309,562$ Deferred revenue $34,613$ $-$ Refundable advance $ (20,465)$ Net cash provided by operating activities $(2,663,241)$ $3,611,840$ Cash flows from investing activities $(2,663,241)$ $3,611,840$ Cash flows from investing activities $(2,750,972)$ $(82,497)$ Net cash provided by (used in) investing activities $(2,750,972)$ $(82,497)$ Net cash provided by (used in) investing activities $1,008,225$ $(98,670)$ Cash flows from financing activities $1,008,225$ $(98,670)$ Net cash provided by (used in) investing activities (351) $(1,811,771)$ Repayment of loan payable (351) $(1,900,318)$ NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS $(1,655,367)$ $1,612,852$ Cash and cash equivalents, beginning of the year $2,797,798$ $1,852,315$ Cash and cash equivalents, end of the year 5 $1,142,431$ 5 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Interest paid during the year 5 $1,781$ 5 $1,873$			
Inventory(6,817)15,706Increase (decrease) in: Accounts payable and accruals Deferred revenue Refundable advance138,950309,562Deferred revenue Refundable advance34,613-(20,465)Net cash provided by operating activities(2,663,241)3,611,840Cash flows from investing activities (Increase) decrease in money market funds purchase of property and equipment Net proceeds (purchases) of investments(950,956)880,905Net cash provided by (used in) investing activities(2,750,972)(82,497)Net cash provided by (used in) investing activities1,008,225(98,670)Cash flows from financing activities1,008,225(98,670)Net cash provided by (used in) investing activities(351)(1,811,771)Repayment of loan payable-(88,547)Net cash used in financing activities(351)(1,900,318)NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS(1,655,367)1,612,852Cash and cash equivalents, beginning of the year2,797,7981,852,315Cash and cash equivalents, end of the year\$ 1,142,431\$ 3,465,167SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Interest paid during the year\$ 1,781\$ 1,873			
Increase (decrease) in: Accounts payable and accruals Deferred revenue Refundable advance138,950 34,613309,562 34,613Net cash provided by operating activities			
Accounts payable and accruals138,950309,562Deferred revenue34,613-Refundable advance-(20,465)Net cash provided by operating activities(2,663,241)3,611,840Cash flows from investing activities(950,956)880,905Purchase of property and equipment(2,750,972)(82,497)Net proceeds (purchases) of investments4,710,153(897,078)Net cash provided by (used in) investing activities1,008,225(98,670)Cash flows from financing activities(351)(1,811,771)Repayment of loan payable-(85,547)Net cash used in financing activities(351)(1,900,318)NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS(1,655,367)1,612,852Cash and cash equivalents, beginning of the year2,797,7981,852,315Cash and cash equivalents, end of the year\$ 1,142,431\$ 3,465,167SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Interest paid during the year\$ 1,781\$ 1,873	Inventory	(6,817)	15,706
Deferred revenue $34,613$ Refundable advance(20,465)Net cash provided by operating activities(2,663,241)(Increase) decrease in money market funds(950,956)Purchase of property and equipment(2,750,972)Net ross of property and equipment(2,750,972)Net cash provided by (used in) investing activities(897,078)Net cash provided by (used in) investing activities1,008,225Net cash provided by (used in) investing activities(351)Net change in line of credit(351)Net cash used in financing activities(351)Net cash used in financing activities(351)Net cash used in financing activities(351)Net (ash used in financing activities(351)Net cash used in financing activities(351)Net cash used in financing activities(351)Cash and cash equivalents, beginning of the year2,797,7982,797,7981,852,315Cash and cash equivalents, end of the year\$ 1,142,431S3,465,167SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:\$ 1,781Interest paid during the year\$ 1,781S1,873			
Refundable advance		138,950	309,562
Net cash provided by operating activities(2,663,241)3,611,840Cash flows from investing activities(950,956)880,905Purchase of property and equipment(2,750,972)(82,497)Net proceeds (purchases) of investments4,710,153(897,078)Net cash provided by (used in) investing activities1,008,225(98,670)Cash flows from financing activities1,008,225(98,670)Net change in line of credit(351)(1,811,771)Repayment of loan payable-(88,547)Net cash used in financing activities(351)(1,900,318)NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS(1,655,367)1,612,852Cash and cash equivalents, beginning of the year2,797,7981,852,315Cash and cash equivalents, end of the year\$ 1,142,431\$ 3,465,167SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Interest paid during the year\$ 1,781\$ 1,873		34,613	-
Cash flows from investing activities (Increase) decrease in money market funds (Increase) decrease in money market funds (Increase) decrease in money market funds (Increase) decrease in money market funds (2,750,972) (82,497) (82,497) Net proceeds (purchases) of investments(950,956) (2,750,972) (82,497) (82,497) (897,078)Net cash provided by (used in) investing activities Net change in line of credit Repayment of loan payable(351) (1,811,771) (88,547)Net cash used in financing activities Net cash used in financing activities(351) (1,900,318)NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS Cash and cash equivalents, beginning of the year2,797,798 (1,655,367)Cash and cash equivalents, end of the year\$ 1,142,431 (\$ 3,465,167SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Interest paid during the year\$ 1,781 (\$ 1,873	Refundable advance	 -	 (20,465)
(Increase) decrease in money market funds(950,956) $880,905$ Purchase of property and equipment(2,750,972)(82,497)Net proceeds (purchases) of investments $4,710,153$ (897,078)Net cash provided by (used in) investing activities $1,008,225$ (98,670)Cash flows from financing activities $1,008,225$ (98,670)Net change in line of credit(351)(1,811,771)Repayment of loan payable $-$ (88,547)Net cash used in financing activities(351)(1,900,318)NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS(1,655,367)1,612,852Cash and cash equivalents, beginning of the year $2,797,798$ 1,852,315Cash and cash equivalents, end of the year $$ 1,142,431$ $$ 3,465,167$ SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Interest paid during the year $$ 1,781$ $$ 1,873$	Net cash provided by operating activities	 (2,663,241)	 3,611,840
Purchase of property and equipment(2,750,972)(82,497)Net proceeds (purchases) of investments4,710,153(897,078)Net cash provided by (used in) investing activities1,008,225(98,670)Cash flows from financing activities(351)(1,811,771)Repayment of loan payable-(88,547)Net cash used in financing activities(351)(1,900,318)Net cash used in financing activities(351)(1,900,318)NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS(1,655,367)1,612,852Cash and cash equivalents, beginning of the year2,797,7981,852,315Cash and cash equivalents, end of the year\$ 1,142,431\$ 3,465,167SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Interest paid during the year\$ 1,781\$ 1,873	Cash flows from investing activities		
Net proceeds (purchases) of investments4,710,153(897,078)Net cash provided by (used in) investing activities1,008,225(98,670)Cash flows from financing activities(351)(1,811,771)Net change in line of credit(351)(1,811,771)Repayment of loan payable(351)(1,900,318)Net cash used in financing activities(1,655,367)1,612,852Cash and cash equivalents, beginning of the year2,797,7981,852,315Cash and cash equivalents, end of the year\$ 1,142,431\$ 3,465,167SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Interest paid during the year\$ 1,781\$ 1,873	(Increase) decrease in money market funds	(950,956)	880,905
Net cash provided by (used in) investing activities1,008,225(98,670)Cash flows from financing activities(351)(1,811,771)Net change in line of credit(351)(1,811,771)Repayment of loan payable-(88,547)Net cash used in financing activities(351)(1,900,318)NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS(1,655,367)1,612,852Cash and cash equivalents, beginning of the year2,797,7981,852,315Cash and cash equivalents, end of the year\$ 1,142,431\$ 3,465,167SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Interest paid during the year\$ 1,781\$ 1,873		(2,750,972)	(82,497)
Cash flows from financing activities Net change in line of credit Repayment of loan payable(351)(1,811,771)Net cash used in financing activities(351)(1,900,318)NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS(1,655,367)1,612,852Cash and cash equivalents, beginning of the year2,797,7981,852,315Cash and cash equivalents, end of the year\$ 1,142,431\$ 3,465,167SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Interest paid during the year\$ 1,781\$ 1,873	Net proceeds (purchases) of investments	 4,710,153	 (897,078)
Net change in line of credit Repayment of loan payable(351) -(1,811,771) (88,547)Net cash used in financing activities(351)(1,900,318)NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS(1,655,367)1,612,852Cash and cash equivalents, beginning of the year2,797,7981,852,315Cash and cash equivalents, end of the year\$ 1,142,431\$ 3,465,167SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Interest paid during the year\$ 1,781\$ 1,873	Net cash provided by (used in) investing activities	 1,008,225	 (98,670)
Repayment of loan payable-(88,547)Net cash used in financing activities(351)(1,900,318)NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS(1,655,367)1,612,852Cash and cash equivalents, beginning of the year2,797,7981,852,315Cash and cash equivalents, end of the year\$ 1,142,431\$ 3,465,167SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Interest paid during the year\$ 1,781\$ 1,873	Cash flows from financing activities		
Net cash used in financing activities(351)(1,900,318)NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS(1,655,367)1,612,852Cash and cash equivalents, beginning of the year2,797,7981,852,315Cash and cash equivalents, end of the year\$ 1,142,431\$ 3,465,167SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Interest paid during the year\$ 1,781\$ 1,873	Net change in line of credit	(351)	(1,811,771)
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS (1,655,367) 1,612,852 Cash and cash equivalents, beginning of the year 2,797,798 1,852,315 Cash and cash equivalents, end of the year \$ 1,142,431 \$ 3,465,167 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Interest paid during the year \$ 1,781 \$ 1,873	Repayment of loan payable	 -	 (88,547)
Cash and cash equivalents, beginning of the year2,797,7981,852,315Cash and cash equivalents, end of the year\$ 1,142,431\$ 3,465,167SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Interest paid during the year\$ 1,781\$ 1,873	Net cash used in financing activities	 (351)	 (1,900,318)
Cash and cash equivalents, end of the year\$ 1,142,431\$ 3,465,167SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Interest paid during the year\$ 1,781\$ 1,873	NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(1,655,367)	1,612,852
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Interest paid during the year \$ 1,781 \$ 1,873	Cash and cash equivalents, beginning of the year	 2,797,798	 1,852,315
Interest paid during the year <u>\$ 1,781</u> <u>\$ 1,873</u>	Cash and cash equivalents, end of the year	\$ 1,142,431	\$ 3,465,167
Interest paid during the year <u>\$ 1,781</u> <u>\$ 1,873</u>	SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:		
		\$ 1,781	\$ 1,873
Right-of-use assets received in exchange for operating lease liabilities \$ 412,049 \$ -			
	Right-of-use assets received in exchange for operating lease liabilities	\$ 412,049	\$ -

NOTES TO COMBINED FINANCIAL STATEMENTS

September 30, 2023 And 2022

(1) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GENERAL INFORMATION

ORGANIZATION

Planned Parenthood of Metropolitan Washington, D.C., Inc. ("PPMW") is a non-profit organization committed to providing high-quality, affordable reproductive health care; promoting educational programs that empower all individuals to make informed and responsible reproductive choices. PPMW establishes, maintains, and operates health centers within the Washington, D.C. metropolitan area which provide and furnish reproductive health care and education.

Planned Parenthood Advocates for DC, Maryland and NoVa (*'PPADMV'*) is a separate, 501(c)(4) corporation. Four of the board members are now appointed by PPMW and three are appointed by Planned Parenthood of Maryland, Inc. (*'PPM'*). The purpose of PPADMV is to protect and expand access to reproductive health care and build local power to influence and promote accountability among state and local policy makers.

BASIS OF PRESENTATION

The accompanying financial statements are presented on the accrual basis of accounting, and in accordance with Financial Accounting Standards Board (FASB) ASC 958, Not-for-Profit Entities.

The combined financial statements include the accounts of PPMW and its affiliate, PPADMV. All significant intercompany balances and transactions have been eliminated.

USE OF ESTIMATES

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Accordingly, actual results could differ from those estimates.

CASH AND CASH EQUIVALENTS

PPMW considers all cash, money market funds and other highly liquid investments with initial maturities of three months or less to be cash equivalents. Cash and other highly liquid investments included in investment accounts are classified with investments.

Bank deposit accounts are insured by the Federal Deposit Insurance Corporation (*'FDIC'*) up to a limit of \$250,000. At times during the year, PPMW maintains cash balances in excess of the FDIC insurance limits. Management believes the risk in these situations to be minimal.

INVESTMENTS

Investments are recorded at their readily determinable fair value. Realized and unrealized gains and losses are included in net appreciation (depreciation) on investments in the Statement of Activities and Change in Net Assets. Donated securities are recorded at their fair value on the donation date. Gain or loss on securities sales is computed using the first-in, first-out (FIFO) method, or where possible, the specific identification method.

NOTES TO COMBINED FINANCIAL STATEMENTS – (Continued)

September 30, 2023 And 2022

ACCOUNTS, GRANTS AND PLEDGES RECEIVABLE

Accounts, grants and pledges receivable approximate fair value. The allowance for doubtful accounts is determined based upon an annual review of account balances, including the age of the balance and the historical experience with the customer.

Accounts receivable are recorded at their net realizable value, which approximates fair value. Grants and pledges receivable that are expected to be collected in future years are recorded at fair value, measured as the present value of their future cash flows. The discounts on these amounts are computed using risk-adjusted interest rates applicable to the years in which the promises are received. Amortization of the discounts is included in grants and contribution revenue.

THIRD-PARTYPATIENT RECEIVABLES

Third-party patient receivables are related to billed patient services fees. Patient services fees receivable are reported at the estimated net realizable value from patients and third-party payers for services rendered. An allowance for doubtful accounts (a percentage of the receivables balance) is determined based on past collection experience.

Revenue under third-party payer agreements is subject to audit and retroactive adjustments. Revenues for estimated third-party payer settlements are recorded in the period in which the related services are rendered.

Differences between the estimated amounts accrued and the interim and final settlements are reported in revenues in the year of settlement. Due to the variability in the timing of settlement of these receivables, PPMW does not have a formal policy for considering the receivables past due.

INVENTORY

Inventory consists of medical supplies, contraceptives, and medications held for sale at each of PPMW's clinics. Inventory is recorded at cost using the first-in, first-out (FIFO) method.

PROPERTYAND EQUIPMENT

Property and equipment are stated at cost or estimated fair value at the time of donation. Acquisitions of property and equipment in excess of \$1,000 are capitalized. The cost of maintenance and repairs is recorded as expenses are incurred.

Property and equipment are depreciated on a straight-line basis over the estimated useful lives of the related assets. The classes of assets and their estimated useful lives are as follows:

Building and Improvements	10-40 Years
Furniture and Equipment	3-10 Years
Leasehold Improvements	Original Lease Term

During 2013, PPMW began a capital campaign for the purchase of the new building. PPMW moved into the building in 2017. The building and building costs are recorded at cost and are depreciated over the estimated useful lives on individual additions. All unspent portions from the capital campaign are included in net assets with donor restrictions at fiscal year end.

Management reviews asset carrying amounts whenever events or circumstances indicate that such carrying amounts may not be recoverable. When considered impaired, the carrying amount of the assets is reduced, by a charge to Statement of Activities and Change in Net Assets, to its current fair value.

NOTES TO COMBINED FINANCIAL STATEMENTS – (Continued)

September 30, 2023 And 2022

NET ASSETS

Net assets and revenues, expenses, gains, and losses are classified based on the existence or absence of donor-imposed restrictions. All contributions are considered available for unrestricted use, unless specifically restricted by the donor. Accordingly, net assets of PPMW and changes therein are classified and reported as follows:

Net assets without donor restrictions – include the revenues and expenses associated with the principal mission of PPMW and are segregated as follows:

Undesignated: These may be used by management for any purpose without restriction.

Board Designated: This is a reserve created by the board consisting of bequests that were received without donor restrictions. Revenues and expenses associated with any related transactions are considered undesignated.

Net assets with donor restrictions – include gifts for which restrictions have not been met. Net assets with donor restrictions are limited by donors for a specific purpose or specified period. Also includes gifts and contributions which require, by donor restriction, that the corpus be invested in perpetuity and only the income be made available for program operations in accordance with donor restrictions.

REVENUE RECOGNITION

Clinic fees and sales revenue are based on the premise that PPMW has a performance obligation to provide family planning services to the organization's patients. As compensation for these services, PPMW is entitled to a service fee based on the level of service provided. The patient's copays for the services are generally collected at the point of service and the remaining charges are billed to the patient's commercial insurance or Medicaid. For self-pay patients, fees are collected at the point of service. PPMW generally satisfies the performance obligations on the date the service was rendered.

Patient fees, which consist primarily of fees for family planning services and the sale of contraceptives, are recorded when earned net of any discounts and contractual adjustments. Contractual adjustments represent the difference between the gross fees charged and the net fees received from third-party payors.

Medical and educational services include revenue earned for services provided to patients who may not qualify for services under the Federal and state fee-for-service programs. These services are paid for directly by the patient on a fee sliding scale when appropriate, or by their private health insurance plan. Similar to the government fee-for-service revenue, private health insurance plans generally reimburse at rates other than the PPMW's usual and customary billing rates. Private health insurance revenues are recorded at estimated expected receipt values at the time the services are provided.

PPMW recognizes contributions when cash, securities or other assets; and unconditional promise to give are received. Conditional promises to give – that is, those with a measurable performance or other barrier and right of return – are not recognized until the condition on which they depend has been met. Unconditional contributions are classified as without donor restrictions unless there are donor stipulations that limit the use of the donated assets. Contributions received are recorded as with or without donor restrictions support, depending on the existence and nature of any donor restrictions. Donor-restricted support is reported as an increase in net assets with donor restrictions. When a restriction expires (that is, when a stipulated time restriction ends or purpose restriction is accomplished), net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statement of activities as net assets released from restrictions.

NOTES TO COMBINED FINANCIAL STATEMENTS – (Continued)

September 30, 2023 And 2022

Revenue for the CAPS Justice Fund is distributed by Planned Parenthood Federation of America (PPFA). The funding is to provide abortion services for lower income women and is recognized on a monthly basis based on services performed.

CONTRIBUTED SERVICES

Contributed services consist of pro-bono legal services. Contributed services are recorded at their fair value as of the date of the gift.

LEASES

Operating leases are included in operating lease right-of-use ("ROU") assets and lease liabilities in the statement of financial position. The Organization determines whether an agreement is or contains a lease at lease inception.

ROU assets represent Organization's right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the Organization's leases do not provide an implicit interest rate, the incremental borrowing rate based on the information available at commencement date is used in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the term.

INCOME TAXES

PPMW is exempt from Federal income taxes under Section 501(c)(3) of the Internal Revenue Code. Accordingly, no provision for income taxes has been made in the accompanying financial statements. PPMW is not a private foundation.

For the year ended September 30, 2023, PPMW has documented its consideration of FASB ASC 740-10, Income Taxes, which provides guidance for reporting uncertainty in income taxes and has determined that no material uncertain tax positions qualify for either recognition or disclosure in the financial statements. PPMW's federal information returns are generally subject to examination by the Internal Revenue Service for three years, including the fiscal years ended September 30, 2020, 2021 and 2022, as well as the return to be filed for the fiscal year ended September 30, 2023.

FUNCTIONAL ALLOCATION OF EXPENSES

Expenses, not specifically identified by type, are allocated between program, management and general and fundraising expenses using the following methods. Expenses associated with facilities, including occupancy, are allocated based upon the square footage used by the program, management, and administrative personnel. Human resource and information technology related expenses are allocated to departments based on departmental headcount. All other expenses are allocated based upon estimates made by PPMW's management. Functional expenses fluctuate annually based on the priorities of PPMW.

RISKS AND UNCERTAINTIES

PPMW invests in various investment securities. Investment securities are exposed to various risks such as interest rates, market and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the amounts reported in the financial statements.

NOTES TO COMBINED FINANCIAL STATEMENTS – (Continued)

September 30, 2023 And 2022

FAIR VALUE MEASUREMENT

PPMW adopted the provisions of FASB ASC 820, Fair Value Measurement. FASB ASC 820 defines fair value, establishes a framework for measuring fair value, establishes a fair value hierarchy based on the quality of inputs (assumptions that market participants would use in pricing assets and liabilities, including assumptions about risk) used to measure fair value, and enhances disclosure requirements for fair value measurements. PPMW accounts for a significant portion of its financial instruments at fair value or considers fair value in their measurement.

PRIOR YEAR INFORMATION

The financial statements include certain prior year summarized comparative information, in total, but not by net asset class. Such information does not include sufficient detail to constitute a presentation in conformity with accounting principles generally accepted in the United States of America. Accordingly, such information should be read in conjunction with the financial statements of PPMW, as of, and for the year ended, September 30, 2022, from which the summarized information was derived.

NEW ACCOUNTING PRONOUNCEMENT ADOPTED

In 2016, the FASB issued ASU 2016-02, *Leases* (Topic 842). The ASU changes the accounting treatment for operating leases by recognizing a lease asset and lease liability at the present value of the lease payments in the statement of financial position and disclosing key information about leasing arrangements. PPMW adopted this ASU in 2023 and applied the transition method allowed by ASU 2016-02 to adopt this standard as of October 1, 2022.

(2) INVESTMENTS

Investments at fair value consisted of the following at September 30, 2023 and 2022:

	<u>2023</u>	<u>2022</u>
Cash and money market funds	\$ 1,455,630	\$ 504,674
Exchange traded funds	4,054,102	3,542,326
Equity mutual funds	58,140	44,871
U.S. Treasury bills and notes	4,504,237	9,052,084
Mortgage pools	264	302
TOTAL INVESTMENTS	<u>\$10,072,373</u>	<u>\$13,144,257</u>

Included in investment income (loss) for the years ended September 30, 2023 and 2022 are the following:

	<u>2023</u>	<u>2022</u>
Interest and dividends Net appreciation (depreciation) on investments	\$ 131,127 	\$ 154,502 (788,873)
TOTAL INVESTMENT INCOME (LOSS)	<u>\$ 818,440</u>	<u>\$ (634,371</u>)

Investment income (loss) is net of \$31,293 and \$33,079 of investment management fees for the years ended September 30, 2023 and 2022, respectively.

NOTES TO COMBINED FINANCIAL STATEMENTS – (Continued)

September 30, 2023 And 2022

(3) FAIR VALUE MEASUREMENT

In accordance with FASB ASC 820, Fair Value Measurement, PPMW has categorized its financial instruments, based on the priority of the inputs to the valuation technique, into a three-level fair value hierarchy. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).

If the inputs used to measure the financial instruments fall within different levels of hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument. Investments recorded in the Statement of Financial Position are categorized based on the inputs to valuation techniques as follows:

Level 1. These are investments where values are based on unadjusted quoted prices for identical assets in an active market PPMW has the ability to access.

Level 2. These are investments where values are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-based valuation techniques that utilize inputs that are observable either directly or indirectly for substantially the full-term of the investments.

Level 3. These are investments where inputs to the valuation methodology are unobservable and significant to the fair value measurement.

Following is a description of the valuation methodology used for investments measured at fair value. There have been no changes in the methodologies used at September 30, 2023 and 2022.

- Exchange traded funds The fair value is equal to the reported net asset value of the fund, which is the price at which additional shares can be obtained.
- Fixed income bond funds The fair value is equal to the reported net asset value of the fund, which is the price at which additional shares can be obtained.
- Mortgage pools Fair value is based upon current yields available on comparable securities of issuers with similar ratings, the security's terms and conditions, and interest rate and credit risk.

The table below summarizes, by level within the fair value hierarchy, PPMW's investments as of September 30, 2023 and 2022:

	2023			
	Level 1	Level 2	Level 3	<u>Total</u>
Asset Class:				
Cash and money market funds	\$ 1,455,630	\$ -	\$ -	\$ 1,455,63 0
Exchange traded funds	4,054,102	-	-	4,054,102
Equity mutual funds	58,140	-	-	58,140
U.S. Treasury bills and notes	4,504,237	-	-	4,504,237
Mortgage pools		264		264
TOTAL INVESTMENTS	<u>\$10,072,109</u>	<u>\$264</u>	<u>\$ -</u>	<u>\$10,072,373</u>

NOTES TO COMBINED FINANCIAL STATEMENTS – (Continued)

September 30, 2023 And 2022

		202	22	
	Level 1	Level 2	Level 3	Total
Asset Class:				
Cash and money market funds	\$ 504,674	\$ -	\$ -	\$ 504,674
Exchange traded funds	3,542,326	-	-	3,542,326
Equity mutual funds	44,871	-	-	44,871
U.S. Treasury bills and notes	9,052,084	-	-	9,052,084
Mortgage pools		302		302
TOTAL INVESTMENTS	<u>\$13,143,955</u>	<u>\$ 302</u>	<u>\$ -</u>	<u>\$13,144,257</u>

There were no transfers between Levels 1 and 2 during the year ended September 30, 2023 and 2022.

(4) PLEDGES RECEIVABLE

The balance of the pledges for the previous capital campaign was \$1,000 and \$1,000 as of September 30, 2023 and 2022, respectively. Pledges due in more than one year have been recorded at the net present value of the estimated cash flows, using a discount rate of 4.19% and 2.93% as of September 30, 2023 and 2022, respectively.

Pledges received but not collected as of September 30, 2023 and 2022 are due as follows:

	<u>2023</u>	<u>2022</u>
Less than one year	\$1,574,477	\$ 765,170
One to five years	673,000	182,832
Total	2,247,477	948,002
Less: Allowance to discount balance to present value	(62,124)	(12,460)
NET PLEDGES RECEIVABLE	<u>\$2,185,353</u>	<u>\$ 935,542</u>

(5) PROPERTY AND EQUIPMENT

Property and equipment as of September 30, 2023 and 2022 are comprised of the following:

	<u>2023</u>	<u>2022</u>
Land	\$ 5,510,226	\$ 5,510,226
Building and improvements	15,795,958	15,795,958
Furniture and equipment	1,016,902	929,804
Computer equipment	444,150	689,776
Leasehold improvements	1,121,761	1,121,761
Construction in progress	2,508,323	
	26,397,320	24,047,525
Less: Accumulated depreciation	(4,295,238)	(3,969,774)
	<u>\$ 22,102,082</u>	<u>\$ 20,077,751</u>

In April 2023, PPMW purchased a building in Northern Virginia for \$2,260,000 to be refurbished and used as a clinic.

NOTES TO COMBINED FINANCIAL STATEMENTS – (Continued)

September 30, 2023 And 2022

(6) **REFUNDABLE ADVANCE**

On April 10, 2020, PPMW received a loan in the amount of \$1,328,800 under the Small Business Administration's (SBA) Paycheck Protection Program ("**PPP**"). PPMW considered this loan to be a conditional contribution as it expected to meet the criteria for loan forgiveness upon incurring eligible expenditures and when its application was accepted by the SBA. PPMW considered the incurrence of eligible expenses and the acceptance of its application for forgiveness to be barriers in the PPP loan agreement, and as such, would recognize contribution income when these conditions were substantially met. PPMW received notification from the SBA that this PPP loan was forgiven July 1, 2021.

On July 1, 2021, PPMW received a second loan in the amount of \$1,308,335 under PPP. Like the first PPP loan, this loan was considered a conditional contribution with revenue recognition subject to the incurrence of eligible expenses and acceptance of the loan forgiveness of application by the SBA. On March 16, 2022, PPMW received notification from the SBA that this PPP loan was forgiven.

(7) LINE OF CREDIT

PPMW has a line of credit for \$4,500,000 with Atlantic Union Bank. Interest accrues at the London Interbank Offered Rate plus 3% with a floor of 3.25% (7.60% at September 30, 2023). The outstanding balance on the line of credit at September 30, 2023 and 2022 was \$49,649 and \$50,000, respectively. The line matures May 31, 2024. Interest expense on this line of credit was \$1,781 and \$1,873 for the years ended September 30, 2023 and 2022, respectively. The line of credit is secured by unrestricted pledges, grants and gifts. In addition, the line is also secured by a lien on PPMW's mortgaged property under the Deed of Trust. The loan agreements also place restrictions on PPMW's ability to incur additional indebtedness.

(8) NET ASSETS

NET ASSETS WITHOUT DONOR RESTRICTIONS

Net assets without donor restrictions are as follows as of June 30:

	<u>2023</u>	<u>2022</u>
Undesignated	\$29,101,727	\$31,859,935
Board designated	2,967,011	2,581,938
	<u>\$32,068,738</u>	<u>\$34,441,873</u>

NOTES TO COMBINED FINANCIAL STATEMENTS – (Continued)

September 30, 2023 And 2022

NET ASSETS WITH DONOR RESTRICTIONS

Net assets with donor restrictions consisted of the following at September 30, 2023 and 2022:

	<u>2023</u>		<u>2022</u>
Time and purpose restricted:			
Virginia – Building	\$ 693,445	\$	40,000
4th Street Campaign	-		1,000
Education programs	560,546		48,000
Primary care	-		50,000
Public affairs	30,500		-
Abortion Access Fund	286,428		528,488
Patient Navigation	105,000		55,000
Accumulated unrealized gains on endowments	 317,049		210,662
	1,992,968		9 33, 150
Perpetual in nature:			
Endowments	 874,432		874,432
Total net assets with donor restrictions	\$ 2,867,400	<u>\$ 1</u>	,807,582

For the year ended September 30, 2023, net assets were released from donor restrictions by incurring expenses, or through the passage of time, which satisfied the restricted purposes specified by the donors, as follows:

Education programs	\$	307,689
Virginia – Building		570,585
4th Street Campaign		1,000
Abortion Access Fund		1,214,375
Primary care		75,000
Public Affairs – Community Organizing		307,839
Information security		87,844
Patient Navigation		55,000
Staff support		79,185
TOTAL NET ASSETS RELEASED FROM RESTRICTIONS	<u>\$</u> 2	<u>2,698,517</u>

(9) ENDOWMENT

PPMW's endowment consists of donor-restricted endowment funds. As required by GAAP, net assets associated with endowment funds are classified and reported based on the existence or absence of donor-imposed restrictions. The Board of Directors has interpreted the Uniform Prudent Management of Institutional Funds Act (UPMIFA) as requiring the preservation of the fair value of the original gift as of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. As a result of this interpretation, PPMW classifies as permanently restricted net assets (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, and (c) accumulations to the permanent endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund.

NOTES TO COMBINED FINANCIAL STATEMENTS - (Continued)

September 30, 2023 And 2022

In accordance with UPMIFA, the organization considers the following factors in making a determination to appropriate or accumulate donor-restricted endowment funds:

- The duration and preservation of the fund;
- The purpose of the organization and the donor-restricted endowment fund;
- General economic conditions and the possible effect of inflation and deflation;
- The expected total return from income and the appreciation of investments; and
- Investment policies of the organization.

Endowment net asset composition by type of fund as of September 30, 2023 and 2022:

		2023	
	Without Donor Restrictions	With Donor <u>Restrictions</u>	Total
Donor-Restricted Endowment Funds	<u>\$ </u>	<u>\$1,191,481</u>	<u>\$1,191,481</u>
		2022	
	Without Donor Restrictions	With Donor <u>Restrictions</u>	<u>Total</u>
Donor-Restricted Endowment Funds	<u>\$</u>	<u>\$1,085,094</u>	<u>\$1,085,094</u>

Permanently restricted net assets are restricted endowments in which the principal is invested in-perpetuity, and the income is expendable to support general operations.

Changes in endowment net assets for the year ended September 30, 2023 and 2022 are as follows:

	2023				
	Without Donor Restrictions		<u>Total</u>		
Endowment net assets, beginning of year Investment return:	<u>\$</u>	<u>\$1,085,094</u>	<u>\$1,085,094</u>		
Investment income	-	24,634	24,634		
Net appreciation (realized and unrealized)		81,753	81,753		
Total investment return		106,387	106,387		
ENDOWMENT NET ASSETS, END OF YEAR	<u>\$</u>	<u>\$1,191,481</u>	<u>\$1,191,481</u>		

NOTES TO COMBINED FINANCIAL STATEMENTS - (Continued)

September 30, 2023 And 2022

		2022	
	Without Donor Restrictions	With Donor <u>Restrictions</u>	<u>Total</u>
Endowment net assets, beginning of year Investment return:	<u>\$</u>	<u>\$1,246,713</u>	<u>\$1,246,713</u>
Investment income Net appreciation (realized and unrealized)	-	30,664 <u>(192,283</u>)	30,664 <u>(192,283</u>)
Total investment return		(161,619)	<u>(161,619</u>)
ENDOWMENT NET ASSETS, END OF YEAR	<u>\$</u>	<u>\$1,085,094</u>	<u>\$1,085,094</u>

FUNDS WITH DEFICIENCIES

From time to time, the fair value of assets associated with individual donor-restricted endowment funds may fall below the level that the donor or UPMIFA requires the organization to retain as fund of perpetual duration. In accordance with GAAP, there were no deficiencies of this nature as of September 30, 2023 and 2022.

RETURN OBJECTIVES AND RISK PARAMETERS

PPMW has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment while seeking to maintain the purchasing power of the endowment assets. Endowment assets include those assets of donor-restricted funds that the organization must hold in-perpetuity.

Under this policy, as approved by the Board of Directors, the endowment assets are invested in a manner that is intended to protect the principal identified to meet short-term cash flow needs; to protect the purchasing power of capital identified to meet intermediate-term needs; to achieve appreciation in the value of investments with long-term time horizon that is sufficient to offset cumulative impact of inflation on purchasing power over time; to avoid investments and strategies that would compromise PPMW's tax exempt status; and to avoid material investments that are inconsistent with PPMW's mission.

STRATEGIES EMPLOYED FOR ACHIEVING OBJECTIVES

PPMW'S investment strategy is to emphasize net total return; that is, the aggregate return from capital appreciation (both realized and unrealized), dividends, and interest, after investment expenses. PPMW is prepared to accept the risk of short-term volatility in exchange for an increased likelihood of earning a net total return over a 10-year time horizon that fulfills the primary goals for the invested assets, i.e., a net total return of more than 4.5% after inflation and investment expenses.

Consistent with PPMW's perspective, objectives, and time horizon, publicly traded equities, including common stocks, mutual funds, and exchange traded funds investing primarily in common stocks traded on United States exchanges or NASDAQ, should represent 60 to 70% of the portfolio absent a specific vote by the Finance Committee.

Fixed income holdings, bank deposits insured by the FDIC, money market funds, and investment grade publicly traded bonds and preferred stocks (including mutual funds and exchange traded funds investing primarily in investment grade fixed income assets), should represent 30% of the portfolio absent a specific vote by the Finance Committee. Cash, bank deposits that can be accessed without penalty, and money market funds should comprise at least 5% of the portfolio absent a specific vote by the Finance Committee.

NOTES TO COMBINED FINANCIAL STATEMENTS - (Continued)

September 30, 2023 And 2022

SPENDING POLICY AND HOW THE INVESTMENT OBJECTIVES RELATE TO SPENDING POLICY

PPMW has adopted a "total return" approach to the definition of investment income. PPMW's primary goals relating to the invested assets are for the assets to provide at least 3.5% of the average invested assets (calculated based on quarterly invested assets for the prior 3 years) to PPMW's operating budget. In establishing this policy, PPMW considered the long-term expected return on its endowment. Accordingly, PPMW is prepared to accept the risk of short-term volatility in exchange for an increased likelihood of earning a net total return over a 10-year time horizon that fulfills the primary goals for the Invested Assets, i.e., a total return of more than 4.5% after inflation and investment expenses. This is consistent with PPMW's objective to maintain the purchasing power of the endowment assets held in perpetuity or for a specified term as well as to provide additional real growth through new gifts and investment return.

(10) LEASES

LEASE

PPMW leases certain building spaces for clinical services in Washington D.C metropolitan area, which expire at various dates through March 2028.

The following is quantitative data related to the Organization's operating lease for the year ended September 30, 2023:

Operating Lease Amounts:	
Right-of-use asset	\$ 322,703
Lease liability	319,637
Other Information:	
Operating outgoing cash flows for operating leases	\$104,269
Weighted-average remaining lease term	3.49 years
Weighted average discount rate	3.28%

Lease cost information for the year ended June 30, 2023 is as follows:

Operating lease cost <u>\$1</u>	101,203
---------------------------------	---------

NOTES TO COMBINED FINANCIAL STATEMENTS – (Continued)

June 30, 2023 And 2022

The approximate minimum annual rental payments under the leases are as follows:

<u>Year Ending June 30,</u>	Amounts Per Lease <u>Agreements</u>
2024	\$ 107,198
2025	110,209
2026	54,362
2027	43,990
2028	22,267
Total undiscounted cash flows	338,026
Less: present value adjustment	(18,389)
Lease liability	<u>\$ 319,637</u>

(11) CONTRIBUTED SERVICES

PPMW received contributions of legal services which are recorded as support (revenue) and expense. The expense was charged to the programs and activities to which the services relate based on the fair value of those services. During the years ended September 30, 2023 and 2022, total donated services were approximately \$179,300 and \$55,500, respectively.

(12) PENSION PLAN

PPMW participates in a defined contribution plan sponsored by Planned Parenthood Federation of America, Inc. Employees become eligible to participate on the first of the month, coincident with or following the date on which the employee attains age 19 and completes one year of service with PPMW. PPMW matches 50% of the employee's contribution up to 6% of the employee's salary. Total employer contributions to the plan totaled approximately \$176,700 and \$169,200 for the years ended September 30, 2023 and 2022, respectively.

(13) AFFILIATED ORGANIZATIONS

Annually, PPMW receives from PPFA a percentage of donations made to the Federation from individuals residing in regions serviced by the organization. For the years ended September 30, 2023 and 2022, the organization received contributions of \$2,394,727 and \$2,950,181, respectively. In addition, PPMW received \$601,630 and \$118,000 for the years ending September 30, 2023 and 2022, respectively, for the Consortium of Abortion Providers (CAPS) funding which is administered by PPFA. PPMW also received \$1,314,201 and \$851,132 in various grants from PPFA during the years ended September 30, 2023 and 2022, respectively.

Dues paid to PPFA were \$93,624 and \$47,600 for the years ended September 30, 2023 and 2022, respectively. PPOL dues were \$36,000 for the years ended September 2023 and 2022, respectively.

NOTES TO COMBINED FINANCIAL STATEMENTS – (Continued)

September 30, 2023 And 2022

PPMW is reimbursed by PPM for services performed and certain costs incurred on their behalf. At September 30, 2023 and 2022, \$52,228 and \$102,367, respectively, was due from PPM. PPM was reimbursed for costs incurred on behalf of PPMW for services they provided to PPADMV. PPADMV owed \$13,219 and \$14,039 to PPM at September 30, 2023 and 2022, respectively. During the year ended September 30, 2022, PPM granted \$70,000 to PPADMV which was in contributions receivable as of September 30, 2023 and 2022.

PPMW paid dues to Planned Parenthood Advocates of Virginia ("*PPAV*") of \$50,000 and \$33,333 for the years ended September 30, 2023 and 2022, respectively. At September 30, 2022, \$12,500 was due to PPAV. PPADMV made a contribution to PPAV for \$50,000 for the year end September 30, 2022.

(14) FINANCIAL ASSETS AND LIQUIDITY RESOURCES

The following table reflects PPMW's financial assets as of September 30, 2023 and 2022, reduced by amounts that are not available to meet general expenditures within one year of the statement of financial position date because of contractual and/or donor restrictions.

Financial Assets

	<u>2023</u>	<u>2022</u>
Cash and cash equivalents	\$ 1,142,431	\$ 2,797,798
Contributions receivable, current portion	1,547,477	765,170
Grants receivable	334,623	221,251
Accounts receivable, net	234,072	308,542
Other receivables	74,603	103,567
Investments	10,072,373	13,144,257
Total financial assets	13,405,579	17,340,585
Donor-restricted endowment funds	(1,191,481)	(1,085,094)
Board designated reserves	(2,967,011)	(2,581,938)
Financial assets available to meet general expenditures		
within one year	<u>\$_9,247,087</u>	<u>\$13,673,553</u>

PPMW strives to maintain liquid financial assets to be available as its general expenditures, liabilities and other obligations become due. PPMW has \$2,967,011 and \$2,581,938 of board designated funds as of September 30, 2023 and 2022, respectively, which could be made available, if necessary, with Board approval. In addition, PPMW maintains a line of credit for \$4,500,000 which can be drawn upon if needed.

(15) SUBSEQUENT EVENTS

Subsequent events after the combined statement of financial position date through the date the financial statements were available for issuance, May 31, 2024, have been evaluated in the preparation of the financial statements.

SUPPLEMENTAL INFORMATION

taitweller.com



REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS ON SUPPLEMENTAL INFORMATION

Board of Directors Planned Parenthood of Metropolitan Washington, D.C., Inc. and Affiliate Washington, D.C.

We have audited the combined financial statements of Planned Parenthood of Metropolitan Washington, D.C., Inc, and affiliate as of and for the year ended September 30, 2023 and our report thereon dated May ____, 2024, which expressed an unmodified opinion on those financial statements, appears on Page 1. Our audit was conducted for the purpose of forming an opinion on the 2023 combined financial statements as a whole. The combining statements of financial position and combining statements of activities and changes in net assets is presented for the purpose of additional analysis and is not a required part of the 2023 financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the combined financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated in all material respects in relation to the financial statements as a whole.

Tait. Weller & Baher CCP

Philadelphia, Pennsylvania May 31, 2024

COMBINING STATEMENT OF FINANCIAL POSITION

September 30, 2023

ASSETS	Planned Parenthood	PPADMV	Elimination	Total
Cash and cash equivalents	\$ 446,399	696,032	\$ -	\$ 1,142,431
Contributions receivable, net	2,067,119	118,234	-	2,185,353
Grants receivable	334,623			334,623
Patient receivables, net	234,072	-	-	234,072
Other receivables	136,701	-	(62,098)	74,603
Prepaid expenses and other current assets	568,797	-	-	568,797
Investments	10,072,373	-	-	10,072,373
Inventory	289,957	-	-	289,957
Operating right-of-use assets	322,703	-	-	322,703
Property and equipment, net of accumulated depreciation	22,102,083			22,102,083
Total assets	\$ 36,574,827	814,266	\$ (62,098)	\$ 37,326,995
LIABILITIES AND NET ASSETS				
LIABILITIES				
Lines of credit	\$ 49,649	-	\$ -	\$ 49,649
Accounts payable and accruals	1,942,134	106,922	(62,098)	1,986,958
Deferred revenue	34,613	-	-	34,613
Lease liabilities	319,637			319,637
Total liabilities	2,346,033	106,922	(62,098)	2,390,857
COMMITMENTS				
NET ASSETS				
Without donor restrictions	31,361,394	707,344	-	32,068,738
With donor restrictions	2,867,400			2,867,400
Total net assets	34,228,794	707,344		34,936,138
Total liabilities and net assets	\$ 36,574,827	814,266	\$ (62,098)	\$ 37,326,995

COMBINING STATEMENT OF ACTIVITIES AND CHANGES IN NET ASSETS

For the Year Ended September 30, 2023

REVENUES, GAINS AND OTHER SUPPORT	Without Donor Restrictions	With Donor Restrictions	Planned Parenthood Total	PPADMV	Eliminating Entries	Total
Contributions	\$ 7,777,115	\$ 2,420,610	\$ 10,197,725	\$ 363,099	\$ -	\$ 10.560.824
Grants and contracts revenue	1,129,108	1,231,338	2,360,446	\$ 303,099 7,500	5 -	2,367,946
Government assistance	1,129,100	1,231,330	2,300,440	7,500		2,307,740
Interest and dividend income	106,493	24,634	131,127	-	-	131,127
Contributed services	179,332	-	179,332	-	-	179,332
Patient service fees, net of charge adjustments	6,634,630	-	6,634,630	-	-	6,634,630
Other revenue	372,935	-	372,935	10,243	(285,658)	97,520
	16,199,613	3,676,582	19,876,195	380,842	(285,658)	19,971,379
Net assets released from restrictions	2,698,517	(2,698,517)				
TOTAL REVENUES, GAINS AND OTHER SUPPORT	18,898,130	978,065	19,876,195	380,842	(285,658)	19,971,379
EXPENSES						
Program Services						
Patient Services	14,289,453	-	14,289,453	-	-	14,289,453
External Affairs	1,048,379	-	1,048,379	-	-	1,048,379
Community Education	1,198,754	-	1,198,754	-	-	1,198,754
PPADMV	285,658		285,658	493,555	(285,658)	493,555
Total Program Services	16,822,244		16,822,244	493,555	(285,658)	17,030,141
Supporting Services						
Management and General	2,088,345	-	2,088,345	-	-	2,088,345
Fundraising	2,853,523	-	2,853,523	-	-	2,853,523
Total Supporting Services	4,941,868		4,941,868			4,941,868
TOTAL EXPENSES	21,764,112		21,764,112	493,555	(285,658)	21,972,009
CHANGE IN NET ASSETS FROM OPERATIONS	(2,865,982)	978,065	(1,887,917)	(112,713)	-	(2,000,630)
OTHER CHANGES						
Net appreciation (depreciation) on investments	605,560	81,753	687,313	-	-	687,313
Loss on contributions receivable						
CHANGE IN NET ASSETS	(2,260,422)	1,059,818	(1,200,604)	(112,713)	-	(1,313,317)
NET ASSETS AT BEGINNING OF YEAR	33,621,816	1,807,582	35,429,398	820,057		36,249,455
NET ASSETS AT END OF YEAR	\$ 31,361,394	\$ 2,867,400	\$ 34,228,794	\$ 707,344	\$ -	\$ 34,936,138